IL6 and rheumatoid arthritis: Moreover, miR-155 was recently shown to drive (spontaneous and TNFα-stimulated) pathogenic responses (proliferation as well as IL-1β and IL-6 production) via downregulation of its target FOXO3 [35–37], which acts to suppress these functional outcomes in RA-SFs [38].